Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)

ClinicalTrials.gov ID: NCT00821093

Public ClinicalTrials.gov record NCT00821093. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 12 Week Treatment, Multi-center, Randomized, Parallel Group, Double Blind, Double Dummy Study to Assess the Superiority of Indacaterol (150 µg o.d.) Via a SDDPI in Patients With Moderate to Severe COPD, Using Salmeterol (50 µg b.i.d.) as an Active Comparator Delivered Via a DISKUS Inhaler

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study compared the safety and efficacy of indacaterol 150 µg taken once daily (o.d.) versus salmeterol 50 µg taken twice daily (b.i.d) in patients 40 years old or older with chronic obstructive pulmonary disease.

Study identification

NCT ID
NCT00821093
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
1,123 participants

Conditions and interventions

Eligibility (public fields only)

Age range
40 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2008
Primary completion
Sep 30, 2009
Completion
Sep 30, 2009
Last update posted
Aug 17, 2011

2009

United States locations

U.S. sites
74
U.S. states
31
U.S. cities
72
Facility City State ZIP Site status
Novartis Investigator Site Anniston Alabama 36207-5710
Novartis Investigator Site Fairhope Alabama 36532
Novartis Investigator Site Jasper Alabama 35501
Novartis Investigator Site Mobile Alabama 36604
Novartis Investigator Site Glendale Arizona 85306
Novartis Investigator Site Phoenix Arizona 85006
Novartis Investigator Site Buena Park California 90620
Novartis Investigator Site Encinitas California 92024
Novartis Investigator Site Fullerton California 92535
Novartis Investigator Site Rancho Mirage California 92270
Novartis Investigator Site Riverside California 92506
Novartis Investigator Site San Diego California 92120
Novartis Investigator Site Torrance California 90505
Novartis Investigator Site Walnut Creek California 94598
Novartis Investigator Site Fort Collins Colorado 80528
Novartis Investigative Site Wheat Ridge Colorado 80033
Novartis Investigative Site Stamford Connecticut 06902
Novartis Investigative Site Newark Delaware 19713
Novartis Investigative Center Clearwater Florida 33765
Novartis Investigative Site Pensacola Florida 32504
Novartis Investigative Site Pensacola Florida 32514
Novartis Investigative Site South Miami Florida 33143
Novartis Investigative Site Tamarac Florida 33321
Novartis Investigative Site Tampa Florida 33603
Novartis Investigative Site Tampa Florida 33613
Novartis Investigative Site Marietta Georgia 30060
Novartis Investigator Site Normal Illinois 61761
Novartis Investigator Site River Forest Illinois 60305
Novartis Investigator Site Skokie Illinois 60076
Novartis Investigator Site Olathe Kansas 66061
Novartis Investigator Site Wichita Kansas 67207
Novartis Investigator Site Madisonville Kentucky 42431
Novartis Investigator Site New Orleans Louisiana 70115
Novartis Investigator Site Opelousas Louisiana 70570
Novartis Investigative Site Baltimore Maryland 21236
Novartis Investigator Site Ann Arbor Michigan 48106
Novartis Investigator Site Livonia Michigan 48152
Novartis Investigator Site Minneapolis Minnesota 55407
Novartis Investigator Site Saint Charles Missouri 63301-2847
Novartis Investigator Site St Louis Missouri 63141
Novartis Investigator Site Lincoln Nebraska 68510
Novartis Investigator Site Omaha Nebraska 68134
Novartis Investigator Site Henderson Nevada 89014
Novartis Investigative Site Reno Nevada 89502
Novartis Investigative Site Cherry Hill New Jersey 08003
Novartis Investigative Site Summit New Jersey 07901
Novartis Investigator Site Albuquerque New Mexico 87108
Novartis Investigative Site Larchmont New York 10538
Novartis Investigative Site Charlotte North Carolina 28207
Novartis Investigative Site Hickory North Carolina 28601
Novartis Investigative Site Raleigh North Carolina 27607
Novartis Investigative Site Shelby North Carolina 28150
Novartis Investigator Site Cincinnati Ohio 45245
Novartis Investigator Site Columbus Ohio 42313
Novartis Investigator Site Willoughby Hills Ohio 44094
Novartis Investigator Site Tulsa Oklahoma 74135-2920
Novartis Investigator Site Eugene Oregon 97404
Novartis Investigator Site Medford Oregon 97504-8741
Novartis Investigator Site Portland Oregon 97213
Novartis Investigative Site Erie Pennsylvania 16506
Novartis Investigative Site Charleston South Carolina 29412
Novartis Investigative Site Greenville South Carolina 29615
Novartis Investigative Site North Charleston South Carolina 29406-7108
Novartis Investigative site Spartanburg South Carolina 29303
Novartis Investigative Site Union South Carolina 29379
Novartis Investigator Site El Paso Texas 79903
Novartis Investigator Site Fort Worth Texas 76104
Novartis Investigator Site Houston Texas 77024
Novartis Investigator Site San Antonio Texas 78212
Novartis Investigative Site Abingdon Virginia 24210
Novartis Investigative Site Richmond Virginia 23229
Novartis Investigator Site Spokane Washington 99204
Novartis Investigator Site Tacoma Washington 98405-4266
Novartis Investigator Site Milwaukee Wisconsin 53209-0996

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 70 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00821093, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 17, 2011 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00821093 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →